Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.58 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.58 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | HNF4A | P41235 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950108 | 0.94 | ALDH1A1 (0.48) | PRSS1PRSS2PRSS3PLA2G2APLA2G10 | |
| SCHEMBL7136015 | 0.91 | PRSS1 (0.47) | PRSS1PRSS2PRSS3PLA2G2APLA2G10 | |
| SCHEMBL27899250 | 0.86 | PLA2G10 (0.50) | PRSS1PRSS2PRSS3PLA2G2APLA2G10 | |
| SCHEMBL1926951 | 0.84 | FOLH1 (0.66) | PRSS1PRSS2PRSS3PLA2G2ACA1 | |
| SCHEMBL1319907 | 0.82 | LMNA (0.64) | PLA2G2APLA2G10LMNAHNF4ACALM1 | |
| SCHEMBL2379457 | 0.81 | TRPA1 (0.62) | PRSS1PRSS2PRSS3PLA2G2APLA2G10 | |
| SCHEMBL6190226 | 0.81 | LMNA (0.69) | PRSS1PRSS2PRSS3PLA2G2APLA2G10 | |
| SCHEMBL4224616 | 0.81 | PLA2G2A (0.69) | PRSS1PRSS2PRSS3PLA2G2APLA2G10 | |
| SCHEMBL7969088 | 0.81 | AKR1B1 (0.54) | LMNACA2FOLH1ALDH1A1TSHR | |
| SCHEMBL8665440 | 0.81 | PRSS1 (0.58) | PRSS1PRSS2PRSS3PLA2G2APLA2G10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114853627-B | Substituted docosahexaenoic amide ethyl benzoate derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2023-06-20 | — | — | CN | claimed |
| CN-114853627-A | Substituted docosahexaenoic acid diethyl ester derivative as well as preparation method and application thereof | 自然资源部第三海洋研究所 | 2022-08-05 | — | — | CN | claimed |
| US-11834392-B2 | KDM4B inhibitors for the treatment of inflammatory diseases and disorders | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2023-12-05 | — | — | US | disclosed |
| CN-114853627-B | Substituted docosahexaenoic amide ethyl benzoate derivative and preparation method and application thereof | 自然资源部第三海洋研究所 | 2023-06-20 | — | — | CN | disclosed |
| CN-114853627-A | Substituted docosahexaenoic acid diethyl ester derivative as well as preparation method and application thereof | 自然资源部第三海洋研究所 | 2022-08-05 | — | — | CN | disclosed |
| US-20220119344-A1 | KDM4B INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT D/B/A ZUCKER INSTITUTE FOR INNOVATION COMMERCIALIZATION | 2022-04-21 | — | — | US | disclosed |
| EP-1208104-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMA (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6548494-B1 | 3,4-dihydro-2H-(1,4)diazepino(6,7,1-hi)indol-1-one or 1-thione derivatives where indole C3 could also be N; use treating cancers as well as stroke, head trauma, and neurodegenerative diseases | AGOURON PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| EP-1208104-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001016136-A2 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119344-A1 | KDM4B INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | KDM1B, KDM4B, KDM3B | PRSS1 3552/4885PRSS2 4262/4885PRSS3 4291/4885 |
| US-11834392-B2 | KDM4B inhibitors for the treatment of inflammatory diseases and disorders | KDM1B, KDM4B, KDM3B | PRSS1 3552/4885PRSS2 4262/4885PRSS3 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.